Press Release

BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPC IN

Lupin Appoints Yugesh Goutam as President – Global HR

Mumbai, June 07, 2016: Pharma major Lupin Limited today announced the appointment of Yugesh Goutam as President – Global Human Resources (HR). Yugesh will lead the HR function for Lupin globally and will be based at the company's corporate headquarters in Mumbai, India. Yugesh takes over from Mr. Divakar Kaza who has opted to retire after a transition period to pursue other interests.

Yugesh comes to Lupin from the JSW Group where he was Group President – Human Resources with responsibility for the HR function across all their businesses. He has over 29 years of diverse experience across sectors and geographies. Prior to JSW he worked with RPG Life Sciences, Beckton Dickenson, Pfizer and Reliance Industries. Yugesh has a track record of developing & sustaining scalable leading edge HR systems/practices for large scale businesses across the globe. He has completed his Post Graduate Diploma in Personnel Management and Industrial Relations from CBM, Chandigarh. He has also done a Human Resources executive program from the University of Michigan, USA in 1998.

Commenting on the appointment, Mr. Nilesh Gupta, Managing Director, Lupin Limited said, *"We are very happy to have Yugesh join Lupin at a time where we are not only building on our leadership in key markets but also expanding our geographical presence, as we continue on our transformational journey to emerge as a specialty pharmaceutical and complex generics major globally. We are already recognized as one of the best companies to work for in Asia and are confident that Yugesh will continue to build on our HR processes and systems, adding depth to deliver a world-class people driven organization."*

About Lupin Limited

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing top 10 generics player in the US (5.51% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales globally. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan (ranked 9th) and South Africa (ranked 4th – IMS Health).

For the financial year ended 31st March 2016, Lupin's Consolidated turnover and Profit after Tax were Rs. 137,016 million (USD 2.09 billion) and Rs. 22,707 million (USD 347 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinlimited

CIN: L24100MH1983PLC029442 Registered Office: Kalpataru Inspire, 3rd Floor, Off Western Express Highway, Santacruz (East), Mumbai - 400 055.

Press Release

BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPC IN

For further information or queries, please contact -

Shamsher Gorawara
Head – Corporate Communications
Lupin Limited:
Ph: +91 98 20 338 555
Email: shamshergorawara@lupin.com

Safe Harbor Statement